Autres langues Algernon Pharmaceuticals Inc.

Actions

AGN

CA01559R4008

Marché Fermé - Canadian Securities Exchange Autres places de cotation 18:35:24 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,13 ^CAD	+8,33 %		+44,44 %	+100,00 %

01/04	Algernon Pharmaceuticals ira de l'avant avec son programme de recherche sur le médicament psychédélique DMT pour les accidents vasculaires cérébraux comme principal actif	CI
27/03	Algernon Pharmaceuticals annonce que l'acquisition du programme d'ifenprodil a été complétée par une entreprise américaine	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024	25/04
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024	24/04
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024	11/04
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	10/04
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding	03/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset	01/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	01/04
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment	28/03
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	27/03
Canadian Investment Regulatory Organization Trade Resumption - AGN	27/03
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position	27/03
Canadian Investment Regulatory Organization Trading Halt - AGN	27/03
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	27/03
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	25/01
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	24/01
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	29/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Algernon Pharmaceuticals Inc.

Actions

AGN

CA01559R4008

Autres langues

Filtres